304 PATENT ABSTRACTS

are made from purified flagellar (H) antigen solutions. The immunoglobulin-G-containing preparations contain flagellar (H) antibodies ob- tained from the blood plasma of human donors or mammals immunized with protective flagellar (H) antigens. They can be purified by methods of affinity chromatography.

4946774

P R O C E S S F O R D E T E C T I N G C A N C E R A N D F O R M O N I T O R I N G

T H E E F F E C T I V E N E S S O F C A N C E R T H E R A P Y

the preparation of said hybridoma cell lines, the use of the monoclonal antibodies and their derivatives for the qualitative and quantitative determination of IgE-BFs, test kits containing the monoclonal antibodies and/or their derivatives, the use of the monoclonal antibodies for the purification of IgE-BFs, the use of purified IgE-BFs, its individual optionally glycosylated proteins and/or fragments thereof for the prevention and/or treatment of allergy, and to pharmaceutical preparations containing them. IgE-BFs and monoclonal antibodies reac- ting with IgE-BF are important for the diagnosis and therapy of allergic diseases.

Se-Kyung Oh assigned to Trustees of Boston University

A process for detecting cancer in a human pat- ient is provided wherein a blood serum is recovered from the patient and is reacted with a monoclonal antibody comprising anti- haptoglobin variant under conditions to effect an immunoreaction when an immunosuppres- sive factor having a molecular weight of about 50K Daltons is present in the serum. The pre- sence ofimmunosuppressive factor at concentra- tion levels substantially exceeding normal concentration levels indicates the existence of immunoincompetence due to widely spread cancer. The effectiveness of cancer therapy is monitored by monitoring the change in levels of the immunosuppressive haptoglobin variant fac- tor in the serum from the patient being treated.

~ 4 6 ~ 8

4946828

N O V E L I N S U L I N P E P T I D E S

Ja Markussen, Herlev, Denmark assigned to Novo Nordisk A/S

Insulin derivatives having a charge which is posi- tive compared with the charge of human insulin at neutral pH, can be used to prepare solutions having prolonged insulin action. In the novel in- sulin derivatives, a basic amino acid has been substituted in the B27-position and/or a neutral amino acid has been inserted in the A4-, A17-, B13- and/or B21-position. Furthermore, the C- terminal carboxyl group of the B-chain may be blocked with an amido or ester residue.

P U R I F I E D I M M U N O G L O B U L I N - R E L A T E D F A C T O R , N O V E L

M O N O C L O N A L A N T I B O D I E S , H Y B R I D O M A C E L L L I N E S ,

P R O C E S S E S A N D A P P L I C A T I O N S

Gu Delespesse, Winnipeg, Canada assigned to Ciba-Geigy Corporation

The invention relates to novel purified human immunoglobulin E binding factors (IgE-BFs), its individual optionally glycosylated proteins, and fragments thereof, processes for the purification of IgE-BFs, novel monoclonal antibodies to lymphocyte cellular receptors for IgE (Fc ep- silonR) crossreacting with IgE-Fs, derivatives thereof, processes for the preparation of these antibodies and their derivatives, hybridoma cell lines that produce these antibodies, processes for

4946835

A N T I F U N G A L F E R M E N T A T I O N P R O D U C T A N D M E T H O D

Charles F Hirsch, Jerrold M Liesch, Michael J Salvatore, Robert Schwartz, David Sesin as- signed to Merck & Co Inc

A novel dioxa diazacyclohexadecenetetrone isolated from the fermentation of a cyano- bacterium (Nostoc sp.) is described. The com- pound is a new antifungal agent with a specificity generally toward filamentous fungi but also ef- fective against Cryptococcus sp.